Azathioprine in Multiple Sclerosis. A Controlled Prospective Study
The “immunosuppressive” treatment of multiple sclerosis (MS) by means of cytostatic medication has been proposed for the past few years [1–3]. A general use of cytostatics in the treatment of diseases which, like MS, display chronic inflammation, can only be justified if it can be proved in carefully controlled studies that this therapy arrests the steadily worsening sufferings of the disease or its fatal course. Such proof has as yet, owing to major methodological difficulties with regard to MS therapy studies, not been given conclusively.
KeywordsPlacebo Neurol Cyclophosphamide Prednisone Haas
Unable to display preview. Download preview PDF.
- 1.Frick E, Angstwurm H, Strauss G (1977) Immunsuppressive Therapie der Multiplen Sklerose. 4. Mitteilung/Behandlungsergebnisse mit Azathioprin und Antilymphocytenglobulin. Munch Med Wochenschr 119:1111–1114Google Scholar
- 6.Pocklington PR (1974) The necessity for, requirements of, and basic design of a general data interpretation and evaluation system. In: Anderson J, Forsythe JM (eds) Medinfo 74. Amsterdam, North Holland Pub & Co, pp 411–418Google Scholar
- 7.Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, Dowell FM, Nagler B, Sibley WA, Tourtellotte WW, Willmon TL (1965) Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 122:552–568CrossRefGoogle Scholar